STAT+: How the first nine drug companies won priority review vouchers from Marty Makary\u2019s FDA
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
WASHINGTON \u2014\u00a0Commissioner Marty Makary wants the Food and Drug Administration to move more quickly. The launch of a new priority review voucher program in June was no exception.\u00a0<\/p>\n
The agency promised winners a one- to two-month review of their drug applications, and speedy reviewer feedback. Interested companies had to prove they aligned with one of several national health priorities, which included addressing a public health crisis, delivering more innovative cures, addressing an unmet medical need, bringing drug manufacturing to the United States, and increasing affordability.\u00a0<\/p>\n
\u201cWe got a tremendous amount of interest nationwide,\u201d Makary told FDA drug regulators at an internal meeting<\/a> in August. \u201cWe didn\u2019t expect the incredible interest we got. The second we announced it, we had people saying, \u2018Where do we apply?\u2019\u201d\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n